Abstract: . . .  hypertrophy in essential hypertension . A meta-analysis of randomized double-blind studies. JAMA 1996;275(19):1507-13. 10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension . Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24): 3255-64. 11. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;28(12):2557-62. 12. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Bakerskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352(9137):1347-51. 13. Feldman RD, Campbell . . .
. . .  3. Pharmacologic treatment of essential hypertension . CMAJ 1993;149(5):575-84. 8. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension : the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353(9153):611-6. 9. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension . A meta-analysis of randomized double-blind studies. JAMA 1996;275(19):1507-13. 10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension . Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24): 3255-64. 11. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in . . .
. . .  Fasting glucose Microalbumin (ACR) Every 2nd yr if BP < 160; Annually if > 160 systolic Lipid ratio TC/HDL LDL-C Triglycerides eGFR TESTS RISK CLINICAL EV ALUA TION Ten-year coronary heart disease risk from risk chart (see over): Consider end-organ damage Eyes; Heart/Circulation; Kidneys: VISIT 1 VISIT 2 VISIT 4 VISIT 3 Based on the Guideline Hypertension . Web site: http://www.health.gov.bc.ca/protoguides/index.html High risk: = 20%, target TC/HDL 4 Moderate risk: < 20%, target TC/HDL 5 Page 6 10-year Coronary Artery Disease Risk (Framingham) 4 6 10 12 5 8 12 16 6 1 0 1 6 2 0 4 8 12 16 5 1 0 1 6 2 0 6 1 2 2  . . .
--3000,3,500,3232,18425